Pfizer buys Biohaven for $11.6 billion
The deal should put an end to the protracted M&A lull in the biotech sector. Piper Sandler analyst Christopher Raymond also thinks so. He believes that the Pfizer deal could restore sentiment about mergers and biotechnology in general.
The U.S. biotech sector experienced its worst April since 2002. COVID-19 is becoming a major cause. Omicron is not such a dangerous strain, and demand for vaccines is falling due to more and more people being fully vaccinated.
